The Swiss -based pharmaceuticals and diagnostics company Roche Holding AG announced headline results from the second and third of eight T-emerge Phase III studies for taspoglutide.

Taspoglutide is the first once-weekly human glucagon-like peptide-1 (GLP-1) analogue being developed to address the important unmet needs of patients with type 2 diabetes. Taspoglutide is similar to the naturally occurring human hormone GLP-1 which plays a key role in blood glucose modulation while slowing down food absorption and suppressing appetite, resulting in glycemic control, weight loss and no incremental risk of hypoglycemia. Taspoglutide is currently in Phase III clinical trials.

The trials show that Roche’s weekly taspoglutide met its primary end-points in a head to head study with sitagliptin (Januvia®), and demonstrated superior HbA1c reduction.

Cross-posted on ASweetLife